Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Gabapentin (GPT), a widely used drug in neurology, has been proposed as a non-hormonal option for the management of hot flushes in menopausal women with contraindications for estrogen therapy. OBJECTIVE: To compare GPT versus low-dose transdermal estradiol (E(2)) for treating post-menopausal women with moderate to very severe hot flushes. METHODS: A total of 45 post-menopausal women with moderate to very severe hot flushes were prospectively and single-blinded randomised to receive oral GPT 600 mg/night or transdermal 25 microg/day E(2) per week. Hot flush intensity and frequency were assessed with the Menopause Rating Scale and a numeric scale respectively at baseline and at 1, 4 and 8 weeks. Side effects were also assessed. RESULTS: Hot flush intensity and frequency significantly decreased for both groups at 1, 4 and 8 weeks of treatment as compared to baseline; however, this decrease was statistically more evident for the E(2) group. Although the percentage of hot flush intensity and frequency reduction at the end of the treatment was higher for E2, this was not statistically significant (68.2% vs. 60.6% for intensity and 70.1% vs. 58.9% for frequency, respectively, p > 0.05, NS). Encountered side effects included: drowsiness, dizziness, fatigue (GPT group) and mastodynia, vaginal spotting and a local allergic reaction (E(2) group). Compliance to treatment was 95.6% (GPT group) as compared to 90.9% for the E(2) group. CONCLUSION: Despite statistical significant differences, from a clinical point of view oral GPT 600 mg was as effective as low-dose transdermal E(2) in controlling moderate to severe hot flushes in post-menopausal women, and should be recommended as an alternative option in those with contraindications to estrogen therapy. More research is warranted in this regard.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
Stearns, V., Beebe, K. L., Iyengar, M., & Dube, E. (2003) · JAMA · doi:10.1001/jama.289.21.2827 · Cited by 496
Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes
Loprinzi, C. L., Sloan, J. A., Perez, E. A., Quella, S. K., Stella, P. J., Mailliard, J. A., Halyard, M. Y., Pruthi, S., Novotny, P. J., & Rummans, T. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1578 · Cited by 473
Reduced thermoregulatory null zone in postmenopausal women with hot flashes.
Freedman, R. R., & Krell, W. (1999) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(99)70437-0 · Cited by 309
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 1×
“Low-dose estrogenic therapy is currently being recommended because these have shown similar positive effects as traditional dosages [10]; however, some women with vasomotor symptoms have absolute contraindications for estrogen therapy or fear their potential adverse effects and do not consent use.”
BackgroundNonhormonal Therapies for Menopausal Hot Flashes: Systematic Review and Meta-analysis
Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006) · JAMA · doi:10.1001/jama.295.17.2057 · Cited by 4
Cited by
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
“Relative efficacy of nonhormonal prescription therapies vs estrogens A limited number of head-to-head RCTs have compared varying estrogen doses, preparations, and routes of administration with nonhormonal agents (213, 240, 244).”
BackgroundRETRACTED: Practice Bulletin No. 141 Management of Menopausal Symptoms
(2014) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000441353.20693.78 · Cited by 434
RetractedMenopausal hot flushes and night sweats: where are we now?
Archer, D. F., Sturdee, D. W., Baber, R., de Villiers, T. J., Pines, A., Freedman, R. R., Gompel, A., Hickey, M., Hunter, M. S., Lobo, R. A., et al. (2011) · Climacteric · doi:10.3109/13697137.2011.608596 · Cited by 185
Shan, D., Zou, L., Liu, X., Shen, Y., Cai, Y., & Zhang, J. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.12.011 · Cited by 55
Metadata
- Authors
- Aguirre, W., Chedraui, P., Mendoza, J., & Ruilova, I.
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2010-01-05
- Volume
- 26
- Issue
- 5
- Pages
- 333-337
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2057968723
- Cited by
- 36
- References
- 6
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.